This post was updated on Jan. 10.
Long Grove Pharmaceuticals launched a single-pack presentation of its second generic to market, carboprost tromethamine injection, USP.
The drug became commercially available in November. Carboprost tromethamine injection, USP is FDA approved and AP rated, and is therapeutically equivalent to Pfizer’s Hemabate. Carboprost tromethamine injection, USP is available in a vial presentation, is compliant with the Trade Agreements Act and made in Canada.
“We are thrilled to offer the first single-pack presentation of carboprost tromethamine to continue to provide flexibility to hospitals, pharmacy departments and patients,” Dan Robins, PhD, the president and CEO of Long Grove Pharmaceuticals, said in a statement. “Utilizing our team’s extensive experience in supply chain management and commercial insight, we remain focused on bringing even more flexibility to the market through product presentations like this.”
Long Grove Pharmaceuticals’ carboprost tromethamine injection, USP marked the second product launch for the Rosemont, Ill.–based company in 2022. The company focuses on complex generics, including injectables and topical products.
Carboprost tromethamine injection sterile solution, like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital that can provide immediate intensive care and acute surgical facilities. For more information about carboprost tromethamine injection, USP, including the boxed warning for dosing and administration guidance, visit longgrovepharma.com.
